

# Nicolas Penel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/116349/publications.pdf>

Version: 2024-02-01

258  
papers

11,651  
citations

47409

49  
h-index

39744

98  
g-index

309  
all docs

309  
docs citations

309  
times ranked

13367  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1-10.	0.8	1,740
2	Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 5269-5274.	0.8	569
3	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncology</i> , The, 2012, 13, 1133-1140.	5.1	490
4	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. <i>JAMA Oncology</i> , 2018, 4, 93.	3.4	303
5	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	1.3	243
6	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 120-133.	5.1	222
7	Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2485-2492.	0.8	213
8	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1732-1742.	5.1	200
9	Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. <i>Annals of Oncology</i> , 2011, 22, 452-457.	0.6	193
10	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193
11	Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). <i>Oncologist</i> , 2012, 17, 1213-1220.	1.9	182
12	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 446-455.	5.1	182
13	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2012, 17, 260-266.	1.9	170
14	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1070-1080.	5.1	170
15	Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. <i>International Journal of Cancer</i> , 2006, 119, 706-711.	2.3	169
16	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2797-2802.	0.8	153
17	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , 2017, 83, 125-131.	1.3	134
18	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018, 23, 1407-e136.	1.9	127

#	ARTICLE	IF	CITATIONS
19	Pazopanib or methotrexate+vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1263-1272.	5.1	123
20	Primary cardiac sarcomas: A retrospective study of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 128-136.	1.3	122
21	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012, 118, 3330-3336.	2.0	118
22	Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 40-50.	2.0	114
23	Postoperative Radiotherapy in Head and Neck Mucosal Melanoma. <i>JAMA Otolaryngology</i> , 2010, 136, 1219.	1.5	111
24	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. <i>European Journal of Cancer</i> , 2016, 58, 90-96.	1.3	111
25	Multivariate analysis of risk factors for wound infection in head and neck squamous cell carcinoma surgery with opening of mucosa. Study of 260 surgical procedures. <i>Oral Oncology</i> , 2005, 41, 294-303.	0.8	107
26	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 1137-1147.	1.3	104
27	Adult desmoid tumors: biology, management and ongoing trials. <i>Current Opinion in Oncology</i> , 2017, 29, 268-274.	1.1	104
28	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019, 119, 151-157.	1.3	103
29	Sorafenib in patients with progressive epithelioid hemangioendothelioma. <i>Cancer</i> , 2013, 119, 2639-2644.	2.0	97
30	Angiosarcoma: State of the art and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 257-263.	2.0	95
31	Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 457-464.	5.1	93
32	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). <i>Annals of Oncology</i> , 2015, 26, 2168-2173.	0.6	93
33	Risk factors for wound infection in head and neck cancer surgery: A prospective study. <i>Head and Neck</i> , 2001, 23, 447-455.	0.9	89
34	Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015, 51, 742-750.	1.3	86
35	Image-Guided Robotic Stereotactic Body Radiation Therapy for Liver Metastases: Is There a Dose Response Relationship?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e39-e47.	0.4	85
36	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 639-648.	5.1	81

#	ARTICLE	IF	CITATIONS
37	Primary Mucosal Melanoma of Head and Neck: Prognostic Value of Clear Margins. <i>Laryngoscope</i> , 2006, 116, 993-995.	1.1	80
38	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 312-319.	5.1	78
39	Solitary Fibrous Tumors and So-Called Hemangiopericytoma. <i>Sarcoma</i> , 2012, 2012, 1-6.	0.7	77
40	Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. <i>Annals of Oncology</i> , 2011, 22, 1266-1272.	0.6	69
41	Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases. <i>Sarcoma</i> , 2008, 2008, 1-6.	0.7	68
42	Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. <i>Journal of Clinical Oncology</i> , 2012, 30, 996-1004.	0.8	68
43	Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. <i>Cancer</i> , 2014, 120, 3361-3369.	2.0	68
44	Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. <i>BMC Cancer</i> , 2013, 13, 64.	1.1	66
45	Radiotherapy alone for Merkel cell carcinoma: A comparative and retrospective study of 25 patients. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 983-990.	0.6	61
46	Risk factors for early catheter-related infections in cancer patients. <i>Cancer</i> , 2007, 110, 1586-1592.	2.0	60
47	Pronostic factors of synchronous brain metastases from lung cancer. <i>Lung Cancer</i> , 2001, 33, 143-154.	0.9	57
48	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 531-540.	5.1	56
49	Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2008, 37, 135-139.	0.7	54
50	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 23-35.	2.0	52
51	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 456-466.	5.1	51
52	Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach. <i>Oral Oncology</i> , 2004, 40, 890-897.	0.8	50
53	Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate. <i>Annals of Surgical Oncology</i> , 2019, 26, 3526-3534.	0.7	48
54	Bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48

#	ARTICLE	IF	CITATIONS
55	Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. <i>Cancer</i> , 2018, 124, 1179-1187.	2.0	47
56	Prognostic factors among cancer patients with good performance status screened for phase I trials. <i>Investigational New Drugs</i> , 2008, 26, 53-58.	1.2	46
57	Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics. <i>Clinical Cancer Research</i> , 2013, 19, 1190-1196.	3.2	46
58	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. <i>Modern Pathology</i> , 2018, 31, 816-828.	2.9	46
59	O-Mel-Inib: A Cancer-p1e Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma. <i>Investigational New Drugs</i> , 2008, 26, 561-565.	1.2	45
60	A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients. <i>Clinical Cancer Research</i> , 2009, 15, 3633-3639.	3.2	45
61	Head and neck cancer surgery in the elderly "Does age influence the postoperative course?". <i>Oral Oncology</i> , 2010, 46, 92-95.	0.8	45
62	Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). <i>European Journal of Cancer</i> , 2017, 79, 119-128.	1.3	45
63	Imatinib as a Possible Cause of Severe Rhabdomyolysis. <i>New England Journal of Medicine</i> , 2008, 358, 2746-2747.	13.9	43
64	Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors. <i>Modern Pathology</i> , 2013, 26, 502-510.	2.9	42
65	Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever.. <i>Supportive Care in Cancer</i> , 2004, 12, 593-598.	1.0	40
66	Prognostic factors for adult sarcomas of head and neck. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2008, 37, 428-432.	0.7	40
67	Long-term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow-up. <i>Cancer</i> , 2014, 120, 3003-3006.	2.0	40
68	Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. <i>Annals of Oncology</i> , 2013, 24, 537-542.	0.6	39
69	Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. <i>Cancer</i> , 2015, 121, 1654-1661.	2.0	39
70	Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 73-80.	2.0	39
71	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , 2018, 7, 4023-4035.	1.3	39
72	Factors determining length of the postoperative hospital stay after major head and neck cancer surgery. <i>Oral Oncology</i> , 2008, 44, 555-562.	0.8	38

#	ARTICLE	IF	CITATIONS
73	Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1361-1365.	0.6	38
74	Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. <i>BMC Cancer</i> , 2013, 13, 385.	1.1	38
75	<scp>REGOSARC</scp>: Regorafenib versus placebo in doxorubicinâ€refractory softâ€tissue sarcomaâ€”A qualityâ€adjusted time without symptoms of progression or toxicity analysis. <i>Cancer</i> , 2017, 123, 2294-2302.	2.0	38
76	Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. <i>Journal of Surgical Oncology</i> , 2007, 96, 124-129.	0.8	37
77	Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. <i>Investigational New Drugs</i> , 2009, 27, 482-489.	1.2	37
78	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. <i>BMC Cancer</i> , 2015, 15, 700.	1.1	37
79	Angiosarcomas and Taxanes. <i>Current Treatment Options in Oncology</i> , 2007, 8, 428-434.	1.3	36
80	Imaging of the most frequent superficial soft-tissue sarcomas. <i>Skeletal Radiology</i> , 2011, 40, 271-284.	1.2	35
81	Crossed views of burden and emotional distress of cancer patients and family caregivers during palliative care. <i>Psycho-Oncology</i> , 2016, 25, 1278-1285.	1.0	35
82	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 289-298.	0.5	35
83	Psychosocial factors involved in delayed consultation by patients with head and neck cancer. <i>Head and Neck</i> , 2005, 27, 274-280.	0.9	34
84	Oral metronomic cyclophosphamide in elderly with metastatic melanoma. <i>Investigational New Drugs</i> , 2010, 28, 684-689.	1.2	33
85	Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma. <i>British Journal of Cancer</i> , 2011, 104, 1544-1550.	2.9	33
86	Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 21-41.	2.0	33
87	Report of Eight Recent Cases of Locally Advanced Primary Pulmonary Artery Sarcomas: Failure of Doxorubicin-Based Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2008, 3, 907-911.	0.5	32
88	Management of â€œunfavourableâ€ carcinoma of unknown primary site: Synthesis of recent literature. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 213-223.	2.0	31
89	Incidence and time trends of sarcoma (2000â€2013): results from the French network of cancer registries (FRANCIM). <i>BMC Cancer</i> , 2020, 20, 190.	1.1	31
90	Adjuvant radiation therapy in metastatic lymph nodes from melanoma. <i>Radiation Oncology</i> , 2011, 6, 12.	1.2	30

#	ARTICLE	IF	CITATIONS
91	Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs. <i>Investigational New Drugs</i> , 2011, 29, 1414-1419.	1.2	30
92	A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 1157-1165.	0.7	29
93	Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). <i>European Journal of Cancer</i> , 2013, 49, 369-376.	1.3	28
94	Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 125-131.	2.0	28
95	Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. <i>Supportive Care in Cancer</i> , 2008, 16, 387-392.	1.0	27
96	Soft tissue sarcomas or intramuscular haematomas?. <i>European Journal of Radiology</i> , 2009, 72, 44-49.	1.2	27
97	Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 399-406.	0.4	27
98	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , 2010, 28, 76-82.	1.2	26
99	Efficacy and safety of <sup>153</sup> Sm-EDTMP as treatment of painful bone metastasis: a large single-center study. <i>Supportive Care in Cancer</i> , 2018, 26, 751-758.	1.0	26
100	Comparison of Response Evaluation Criteria in Solid Tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: A retrospective analysis. <i>European Journal of Cancer</i> , 2015, 51, 202-209.	1.3	25
101	Prognostic significance of wound infections following major head and neck cancer surgery: an open non-comparative prospective study. <i>Supportive Care in Cancer</i> , 2004, 12, 634-9.	1.0	24
102	Prognosis of hypercalcemia in aerodigestive tract cancers: Study of 136 recent cases. <i>Oral Oncology</i> , 2005, 41, 884-889.	0.8	24
103	“Classical 3+3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents. <i>Investigational New Drugs</i> , 2009, 27, 552-556.	1.2	24
104	Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. <i>British Journal of Cancer</i> , 2010, 102, 1207-1212.	2.9	24
105	What does a modified-Fibonacci dose-escalation actually correspond to?. <i>BMC Medical Research Methodology</i> , 2012, 12, 103.	1.4	23
106	Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. <i>Targeted Oncology</i> , 2014, 9, 273-277.	1.7	23
107	Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 62-66.	2.0	23
108	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23

#	ARTICLE	IF	CITATIONS
109	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). <i>Oncotarget</i> , 2016, 7, 73984-73994.	0.8	23
110	Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. <i>BMC Cancer</i> , 2015, 15, 127.	1.1	22
111	Previous chemotherapy as a predictor of wound infections in nonmajor head and neck surgery: Results of a prospective study. <i>Head and Neck</i> , 2004, 26, 513-517.	0.9	20
112	Palliative Chemotherapy Does Not Improve Survival in Metastatic Esophageal Cancer. <i>Oncology</i> , 2010, 79, 46-54.	0.9	20
113	Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 242-248.	2.0	20
114	Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy. <i>Investigational New Drugs</i> , 2012, 30, 403-404.	1.2	20
115	A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 900-909.	1.2	20
116	The off-label use of targeted therapies in sarcomas: the OUTCâ€™MS program. <i>BMC Cancer</i> , 2014, 14, 870.	1.1	20
117	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2017, 35, 102-102.	0.8	20
118	Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. <i>Gynecologic Oncology</i> , 2022, 166, 211-218.	0.6	20
119	A paradigm shift in tumour response evaluation of targeted therapy. <i>Current Opinion in Oncology</i> , 2012, 24, 338-344.	1.1	19
120	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. <i>Annals of Oncology</i> , 2013, 24, 2681-2685.	0.6	19
121	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSÃ© pembrolizumab study from Unicancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11520-11520.	0.8	19
122	Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2018, 23, 948-955.	1.9	18
123	Results of APIâ€™Al based regimen in osteosarcoma adult patients included in the French OS2006/Sarcomeâ€™09 study. <i>International Journal of Cancer</i> , 2020, 146, 413-423.	2.3	18
124	Pain burden in desmoid tumor patients: A survey of the French Advocacy Group SOS Desmoid. <i>Bulletin Du Cancer</i> , 2015, 102, 213-216.	0.6	16
125	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021, 150, 108-118.	1.3	16
126	A simple predictive model for postoperative mortality after head and neck cancer surgery with opening of mucosa. <i>Oral Oncology</i> , 2007, 43, 174-180.	0.8	15



#	ARTICLE	IF	CITATIONS
127	Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients. <i>Investigational New Drugs</i> , 2010, 28, 529-530.	1.2	15
128	Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , 2014, 20, 5663-5671.	3.2	15
129	Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. <i>BMC Cancer</i> , 2018, 18, 963.	1.1	15
130	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. <i>ESMO Open</i> , 2020, 5, e000662.	2.0	15
131	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 11507-11507.	0.8	15
132	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
133	Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?. <i>Bulletin Du Cancer</i> , 2012, 99, E100-E106.	0.6	14
134	Non-islet-cell tumour hypoglycaemia (NICTH): About a series of 6 cases. <i>Annales D'Endocrinologie</i> , 2019, 80, 21-25.	0.6	14
135	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021, 21, 631.	1.1	14
136	Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients. <i>PLoS ONE</i> , 2009, 4, e6483.	1.1	14
137	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14
138	Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. <i>Medical Oncology</i> , 2012, 29, 3003-3008.	1.2	13
139	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018, 99, 28-36.	1.3	13
140	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. <i>Clinical Cancer Research</i> , 2019, 25, 4611-4615.	3.2	13
141	Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials. <i>Frontiers in Oncology</i> , 2020, 10, 594445.	1.3	13
142	Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials. <i>PLoS ONE</i> , 2011, 6, e16633.	1.1	13
143	Vinorelbine in breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2901-2910.	0.9	12
144	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 295-303.e3.	0.9	12

#	ARTICLE	IF	CITATIONS
145	Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREO-SARC trial protocol. <i>BMJ Open</i> , 2020, 10, e038391.	0.8	12
146	Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). <i>BMC Cancer</i> , 2020, 20, 117.	1.1	12
147	Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR. <i>Oncotarget</i> , 2018, 9, 18296-18308.	0.8	12
148	Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2013, 45, 285-294.	1.3	12
149	Individual Life Expectancy Estimation Using Validated Prognostic Scores for Patients with Cancer of Unknown Primary. <i>Oncology</i> , 2010, 78, 87-93.	0.9	11
150	Pulmonary blastoma in adult: Dramatic but transient response to doxorubicin plus ifosfamide. <i>Acta Oncologica</i> , 2011, 50, 156-157.	0.8	11
151	Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 553-64.	1.7	11
152	Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. <i>BMC Cancer</i> , 2016, 16, 679.	1.1	11
153	Lack of Prognostic Value of <i>CTNNB1</i> Mutation Profile in Desmoid-Type Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4105-4111.	3.2	11
154	Multivariate analysis of risk factors for wound infection in head and neck squamous cell carcinoma surgery with opening of mucosa. Study of 260 surgical procedures. <i>Oral Oncology</i> , 2005, 41, 35-44.	0.7	10
155	Inflation in the number of eligibility criteria for industry-sponsored phase II cancer clinical trial: Illustration over a 20-year period. <i>Contemporary Clinical Trials</i> , 2012, 33, 459.	0.8	10
156	Reporting adverse events in cancer surgery randomized trials: A systematic review of published trials in oesophago-gastric and gynecological cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 108-114.	2.0	10
157	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. <i>Scientific Reports</i> , 2017, 7, 17917.	1.6	10
158	Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. <i>International Journal of Cancer</i> , 2019, 145, 2135-2143.	2.3	10
159	Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. <i>European Journal of Cancer</i> , 2022, 160, 134-139.	1.3	10
160	Cancer-associated hypercalcemia: validation of a bedside prognostic score. <i>Supportive Care in Cancer</i> , 2009, 17, 1133-1135.	1.0	9
161	Publication biases and phase II trials investigating anticancer targeted therapies. <i>Investigational New Drugs</i> , 2009, 27, 287-288.	1.2	9
162	Advanced Abrikossoff tumour: A metastatic or a multifocal malignancy?. <i>Acta Oncologica</i> , 2012, 51, 133-135.	0.8	9

#	ARTICLE	IF	CITATIONS
163	Tumor Calcification: A New Response Pattern of Myxoid Liposarcoma to Trabectedin. Case Reports in Oncology, 2014, 7, 204-209.	0.3	9
164	Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1094-1100.	0.6	9
165	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. European Journal of Cancer, 2020, 126, 45-55.	1.3	9
166	Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial.. Journal of Clinical Oncology, 2015, 33, 10504-10504.	0.8	9
167	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Oncotarget, 2015, 6, 26388-26399.	0.8	9
168	Activity endpoints reported in soft tissue sarcoma phase II trials: Quality of reported endpoints and correlation with overall survival. Critical Reviews in Oncology/Hematology, 2013, 88, 309-317.	2.0	8
169	Time interval between surgery and start of adjuvant radiotherapy in patients with soft tissue sarcoma: A retrospective analysis of 1131 cases from the French Sarcoma Group. Radiotherapy and Oncology, 2016, 120, 156-162.	0.3	8
170	Midazolam sedation in palliative medicine: retrospective study in a French center for cancer control. BMC Palliative Care, 2020, 19, 85.	0.8	8
171	ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).. Journal of Clinical Oncology, 2014, 32, 10501-10501.	0.8	8
172	“Sufficient Life Expectancy”: An Amazing Inclusion Criterion in Cancer Phase II-III Trials. Journal of Clinical Oncology, 2009, 27, e105-e105.	0.8	7
173	When cancerophobia and denial lead to death. Palliative and Supportive Care, 2009, 7, 253-255.	0.6	7
174	Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients. Investigational New Drugs, 2011, 29, 700-705.	1.2	7
175	Regorafenib use as a possible cause of intestinal perforation. Acta Oncologica, 2013, 52, 1789-1790.	0.8	7
176	Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study. BMC Cancer, 2015, 15, 218.	1.1	7
177	Maintenance therapy and drug holiday in sarcoma patients: systematic review. Acta Oncologica, 2020, 59, 1084-1090.	0.8	7
178	Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial. Value in Health, 2021, 24, 676-682.	0.1	7
179	The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion. ELife, 2022, 11, .	2.8	7
180	Development of a score that predicts survival among patients with bone metastasis revealing solid tumor. Supportive Care in Cancer, 2008, 16, 1089-1093.	1.0	6

#	ARTICLE	IF	CITATIONS
181	Factors Favouring Palliative Treatment Multidisciplinary Decisions for Newly Diagnosed Visceral and Soft Tissue Sarcomas. <i>Clinical Oncology</i> , 2008, 20, 523-527.	0.6	6
182	Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. <i>Investigational New Drugs</i> , 2010, 28, 178-184.	1.2	6
183	Inappropriate dose of multitargeted tyrosine kinase inhibitors: the original sin. <i>Current Opinion in Oncology</i> , 2016, 28, 437-440.	1.1	6
184	Reappraisal of eligibility criteria in cancer clinical trials. <i>Current Opinion in Oncology</i> , 2018, 30, 352-357.	1.1	6
185	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. <i>Cancers</i> , 2020, 12, 3746.	1.7	6
186	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00613.	1.1	6
187	Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials. <i>Investigational New Drugs</i> , 2010, 28, 839-843.	1.2	5
188	Proposal for size justification of expanded cohort at phase-2-recommended dose. <i>Investigational New Drugs</i> , 2011, 29, 713-715.	1.2	5
189	Prostate cancer related haemophagocytic syndrome: Successful treatment with chemotherapy. <i>Acta Oncologica</i> , 2012, 51, 268-269.	0.8	5
190	Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials. <i>Investigational New Drugs</i> , 2012, 30, 653-661.	1.2	5
191	Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-3.	0.2	5
192	Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI). <i>Oncolmmunology</i> , 2020, 9, 1846914.	2.1	5
193	Desmoid-type fibromatosis: toward a holistic management. <i>Current Opinion in Oncology</i> , 2021, 33, 309-314.	1.1	5
194	Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11508-11508.	0.8	5
195	Participation in randomised clinical trials is linked to emotion regulation strategies. <i>Contemporary Clinical Trials</i> , 2011, 32, 32-35.	0.8	4
196	Major impact of COVID-19 national containment on activities in the French northern comprehensive cancer center. <i>Medical Oncology</i> , 2021, 38, 28.	1.2	4
197	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2565-2565.	0.8	4
198	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- $\beta$ 2 and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2021, 39, 6020-6020.	0.8	4

#	ARTICLE	IF	CITATIONS
199	Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials. PLoS ONE, 2012, 7, e52638.	1.1	4
200	General practitioners assessment of a structured report on medical decision making by a regional multidisciplinary cancer committee. Bulletin Du Cancer, 2007, 94, E23-6.	0.6	4
201	Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM). Cancer, 2022, 128, 2483-2492.	2.0	4
202	Potential clinical activity of pembrolizumab monotherapy in ovarian sex cords, rare epithelial carcinoma, and other rare ovarian tumor histotypes: The French AcSÂ© pembrolizumab study from Unicancer.. Journal of Clinical Oncology, 2022, 40, 5572-5572.	0.8	4
203	Quelques Ã©lÃ©ments particuliers concernant lâ€™Ã©pidÃ©miologie des sarcomes. Oncologie, 2007, 9, 84-87.0.2		3
204	Silent hereditary hemochromatosis as a susceptibility factor of doxorubicin-induced acute cardiac failure. Annals of Oncology, 2010, 21, 2293-2294.	0.6	3
205	Determining the Length of Posttherapeutic Follow-up for Cancer Patients Using Competing Risks Modeling. Medical Decision Making, 2014, 34, 168-179.	1.2	3
206	Metabolic disorders associated with the use of targeted cancer therapies. Current Opinion in Oncology, 2015, 27, 258-266.	1.1	3
207	PRognostic factor of Early Death In phase II Trials or the end of â€”sufficient life expectancyâ€™ as an inclusion criterion? (PREDIT model). BMC Cancer, 2016, 16, 768.	1.1	3
208	First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control. Oncology, 2016, 90, 88-96.	0.9	3
209	Reply to B. Biswas and D. Dabkara. Journal of Clinical Oncology, 2016, 34, 764-765.	0.8	3
210	Trabectedin is an effective second-line treatment in soft tissue sarcoma patients. Annals of Oncology, 2016, 27, 551-552.	0.6	3
211	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. Cancers, 2020, 12, 3647.	1.7	3
212	Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study. Radiotherapy and Oncology, 2022, 168, 95-103.	0.3	3
213	Desmoid tumors located in the abdomen or associated with adenomatous polyposis: French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (SNFGE, FFCD, GERCOR,) Tj ETQq1 1 0.7843143gBT /Over		3
214	Health-related quality of life in patients treated with pembrolizumab for microsatellite instabilityâ€”high/mismatch repairâ€”deficient advanced solid tumours: Results from the KEYNOTE-158 study. European Journal of Cancer, 2022, 169, 188-197.	1.3	3
215	Association head and neck angiosarcoma and nevoid basal cell carcinoma syndrome (Gorlin) Tj ETQq1 1 0.7843143gBT /Overlock 10 Tf	0.7	2
216	Survival prognostic factors for lateral bucco-pharyngeal junction squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2008, 265, 25-28.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter?. <i>Oncology</i> , 2009, 77, 157-161.	0.9	2
218	Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis. <i>Supportive Care in Cancer</i> , 2009, 17, 285-293.	1.0	2
219	What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials. <i>Bulletin Du Cancer</i> , 2014, 101, E19-E24.	0.6	2
220	Lessons from three phase III trials assessing neoadjuvant treatment in sarcoma patients. <i>Annals of Oncology</i> , 2017, 28, 2891-2893.	0.6	2
221	How to emerge from the conservatism in clinical research methodology?. <i>Current Opinion in Oncology</i> , 2017, 29, 400-404.	1.1	2
222	First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. <i>Bulletin Du Cancer</i> , 2017, 104, 552-558.	0.6	2
223	Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial. <i>BMC Cancer</i> , 2018, 18, 775.	1.1	2
224	Personalised management of alveolar soft part sarcoma: a promising phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 750-752.	5.1	2
225	Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3130-3130.	0.8	2
226	Primitive neuroectodermal tumour of the duodenum with unexpected lymph node involvement. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 511-512.	0.6	1
227	Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases. <i>Bulletin Du Cancer</i> , 2015, 102, 730-736.	0.6	1
228	Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 737-737.	0.6	1
229	Symptomatic acute hypotension associated with high-dose dacarbazine. <i>Melanoma Research</i> , 2020, 30, 426-428.	0.6	1
230	Switch in use of midazolam for cancer patients during the COVID-19 pandemic. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1817-1818.	0.5	1
231	Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102960.	2.0	1
232	Two cases of rare late onset life-threatening pseudoprogression with immune check point inhibitors in advanced cancer patients – a case report. <i>Acta Oncologica</i> , 2021, 60, 683-686.	0.8	1
233	ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5046-5046.	0.8	1
234	Prognosis value of S45F mutation of CTNNB1 in desmoid-type fibromatosis (DF): Prospective analysis of 500 consecutive patients (pts) from ALTITUDES trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11510-11510.	0.8	1

#	ARTICLE	IF	CITATIONS
235	Very low seroprevalence of sars-cov-2 among health care personnel (HCP) in a French northern comprehensive cancer center at the end of first national containment.. Journal of Clinical Oncology, 2021, 39, e13604-e13604.	0.8	1
236	Activity of regorafenib in patients with non-adipocytic soft tissue sarcoma (NASTS): Evaluation of heterogeneity of treatment effect on the updated analysis of pooled cohorts.. Journal of Clinical Oncology, 2022, 40, 11555-11555.	0.8	1
237	A lesion suspected of being a desmoid tumor in the context of familial adenomatous polyposis should be biopsied. Digestive and Liver Disease, 2022, , .	0.4	1
238	<i>MBD4</i> deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients: A retrospective study.. Journal of Clinical Oncology, 2022, 40, e21601-e21601.	0.8	1
239	Role of the investigator in phase 1 trials of anticancer drugs. Lancet Oncology, The, 2012, 13, 1177-1179.	5.1	0
240	Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue. Pharmaceutical Medicine, 2016, 30, 143-147.	1.0	0
241	Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors. Pharmaceutical Medicine, 2016, 30, 49-55.	1.0	0
242	â€œImpossibleâ€•patients in oncology: Two unusual cases. Palliative and Supportive Care, 2019, 17, 119-121.	0.6	0
243	Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 958-958.	0.6	0
244	Management of tumor tissue in cancer clinical trials: An ethical perspective. Bulletin Du Cancer, 2019, 106, 1064.	0.6	0
245	Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. Cancer, 2020, 126, 4614-4615.	2.0	0
246	REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas) Tj ETQq0 00TgBT /OVerlock 10	0.8	0
247	Overall survival (OS) and prognostic factors (PF) of patients (pts) with metastatic solid tumors admitted in intensive care unit (ICU).. Journal of Clinical Oncology, 2021, 39, e24074-e24074.	0.8	0
248	Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.. Journal of Clinical Oncology, 2021, 39, 3096-3096.	0.8	0
249	Vaccination coverage in cancer outpatients: An interventional multicenter before/after study.. Journal of Clinical Oncology, 2021, 39, e24026-e24026.	0.8	0
250	Impact of the COVID-19 pandemic on clinical activity during the lockdown in North France: A single center experience.. Journal of Clinical Oncology, 2021, 39, e13594-e13594.	0.8	0
251	â€œTNMâ€•at study entry in phase I trials. Bulletin Du Cancer, 2021, 108, 671-672.	0.6	0
252	High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas. Cancers, 2021, 13, 4841.	1.7	0

#	ARTICLE	IF	CITATIONS
253	Rare bone sarcomas: a retrospective analysis of 145 adult patients from the French Sarcoma Group. International Journal of Cancer, 2021, , .	2.3	0
254	Abstract 1965: Predictive and prognostic value of miRNA expression profile in aggressive fibromatosis treated with imatinib.. , 2013, , .		0
255	Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better. Translational Cancer Research, 2016, 5, S1160-S1162.	0.4	0
256	From rare to well-done: importance of rare tumors in cancer therapeutic advances. Oncotarget, 2019, 10, 3998-3999.	0.8	0
257	Epithelioid Hemangioendothelioma. , 2020, , 113-128.		0
258	REGOMAIN: A randomized, placebo-controlled, double-blinded, multicenter, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients (pts) with high-grade bone sarcomas (HGBS) at diagnosis or relapse and without complete remission after standard treatment.. Journal of Clinical Oncology, 2022, 40, TPS11585-TPS11585.	0.8	0